Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daragh Heitzman

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
JAMA Network Open|February 17, 2025
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical TrialSabrina Paganoni, Christina N Fournier, Eric A Macklin, et al.
JAMA|March 11, 2025
CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial, James D Berry, Nicholas J Maragakis, et al.
JAMA|March 11, 2025
Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial, Jeremy M Shefner, Björn Oskarsson, et al.
Nature Neuroscience|February 4, 2022
Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell linesEmily G Baxi, Terri Thompson, Jonathan Li, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
JAMA Network Open|February 17, 2025
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical TrialSabrina Paganoni, Christina N Fournier, Eric A Macklin, et al.
JAMA|March 11, 2025
CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial, James D Berry, Nicholas J Maragakis, et al.
JAMA|March 11, 2025
Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial, Jeremy M Shefner, Björn Oskarsson, et al.
Nature Neuroscience|February 4, 2022
Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell linesEmily G Baxi, Terri Thompson, Jonathan Li, et al.
Pageof 4